Inclusion Criteria:  Males and females aged between 18 and 75 years (inclusive) LVEF < 0.50  Diagnosis consistent with acute myocarditis including:  Clinical criteria (symptoms of chest pain, arrhythmia or shortness of breath, or history of viral-like illness), preferably followed by elevated troponin in the absence of hemodynamically significant CAD* (defined as a stenosis greater than 50% in a major epicardial coronary artery) within the previous 90 days PLUS CMR diagnosis: (Lake Louise Criterial) OR Endomyocardial biopsy showing either cellular inflammation and/or immunohistochemistry consistent with inflammation Male subjects with partners of childbearing potential who have had a vasectomy or are willing to use double barrier contraception methods during the conduct of the study and for 2 months after the last dose of study drug. Women of childbearing potential willing to use an acceptable method of contraception starting with study drug administration and for a minimum of 2 months after study completion. Otherwise, women must be post- menopausal  Exclusion Criteria:  Coronary artery disease (CAD) defined as a stenosis greater than 50% in a major epicardial coronary artery Severe valvular heart disease Inability to safely undergo CMR including administration of gadolinium Estimated glomerular filtration rate (eGFR) < 30 ml/min Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times the upper limit of normal (ULN) or Alt or AST >3x ULN plus bilirubin >2x ULN. Sepsis, defined as documented bacteremia at the time of presentation or other documented active infection. Severe left ventricular (LV) dysfunction - requiring inotropic support, left ventricular assist device (LVAD) or other circulatory assist devices, or urgent need for transplantation Documented biopsy evidence of giant cell or eosinophilic myocarditis Acute coronary syndrome (ACS) within 30 days Percutaneous coronary intervention (PCI) within 30 days History of QT interval prolongation or QTc interval > 500 msec Treated with strong inducers CYP3A4 or CYP2C19 Current participation in any research study involving investigational drugs or devices Inability or unwillingness to give informed consent Ongoing drug or alcohol abuse Women who are pregnant or breastfeeding Current diagnosis of cancer, with the exception of non-melanoma skin cancer Any factor, which would make it unlikely that the patient can comply with the study procedures. On any cannabinoid during the past month Body weight > 170 kg Showing suicidal tendency as per the C-SSRS, administered at screening